Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KAT7 | O95251 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813159 | 1.00 | HPGDS (0.49) | HPGDSHDAC1HDAC2JAK2JAK1 | |
| SCHEMBL22778224 | 1.00 | HPGDS (0.49) | HPGDSHDAC1HDAC2JAK2JAK1 | |
| SCHEMBL25256330 | 0.79 | POLB (0.44) | HPGDSHDAC1HDAC2JAK2USP30 | |
| SCHEMBL30509998 | 0.79 | POLB (0.44) | HPGDSHDAC1HDAC2JAK2USP30 | |
| SCHEMBL22810473 | 0.77 | PDE4B (0.52) | HPGDSHDAC1HDAC2JAK2JAK1 | |
| SCHEMBL6912658 | 0.77 | GPR119 (0.48) | HPGDSHDAC1HDAC2JAK2JAK1 | |
| SCHEMBL15180524 | 0.77 | TP53 (0.48) | JAK2JAK1 | |
| SCHEMBL22778179 | 0.76 | KCNH2 (0.41) | HDAC1HDAC2 | |
| SCHEMBL14740552 | 0.75 | HTT (0.63) | HPGDSHDAC1HDAC2JAK2JAK1 | |
| SCHEMBL38655393 | 0.75 | GPR119 (0.42) | HPGDSUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| EP-3983392-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX Cardio, LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114206843-A | Compounds for modulating proprotein convertase subtilisin/Kexin type 9(PCSK9) | SRX心脏有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | HPGDS 661/4885HDAC1 929/4885HDAC2 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.